Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an influence on the resolution processes in ARDS patients infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Description: improvement of lung injury score (LIS), 0-16 points, severity increasing with higher points
Measure: lung injury score Time: day 10Description: D-dimers blood levels
Measure: D-dimers Time: day 0, 1, 2, 3, 10 and 15Description: distribution of phenotypes of immune cells
Measure: phenotype Time: day 0, 1, 2, 3, 10 and 15Description: Levels of specialized pro-resolving lipid mediators within alveolar macrophages and bronchoalveolar lavage
Measure: pro-resolving lipid mediators Time: day 0, 1, 2, 3, 10 and 15Description: Cytokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions
Measure: cytokines Time: day 0, 1, 2, 3, 10 and 15Description: Chemokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions
Measure: chemokines Time: day 0, 1, 2, 3, 10 and 15Description: Survival at 10 days and 28 days
Measure: Survival Time: day 10 and 28Description: Time to removal of endotracheal tube
Measure: extubation Time: day 28Description: lymphocyte subpopulations in peripheral blood by flow cytometry prior and after MSC infusion (day 0,3,5,10)
Measure: lymphocyte subpopulations Time: day 0, 3, 5 and 10Description: evaluate SARS-CoV-2-specific antibody titers in the serum of patients prior and post MSC infusion.
Measure: SARS-CoV-2-specific antibody titers Time: day 0, 5 and 10Description: evaluate levels of complement molecules (C5-C9) in the serum of patients prior and post MSC infusion
Measure: complement molecules (C5-C9) Time: day 0, 5 and 10